Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-37822681 dosing study in stable schizophrenia
NCT01812642Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of JNJ-37822681 in schizophrenia, sponsored by Johnson & Johnson. Started Jul 2008; status: completed.
02
Drugs
JNJ-37822681
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01812642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01812642.